Berberis composition for cognitive health
US-2024424045-A1 · Dec 26, 2024 · US
US9044451B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9044451-B2 |
| Application number | US-201113810774-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 19, 2011 |
| Priority date | Jul 19, 2010 |
| Publication date | Jun 2, 2015 |
| Grant date | Jun 2, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of delta tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol in combination with cyclodextrin to a patient in need thereof.
Opening claim text (preview).
What is claimed is: 1. A method for treating lysosomal storage disorder comprising administering to a subject in need thereof a pharmaceutically effective composition comprising δ tocopherol, wherein the composition does not comprise α tocopherol. 2. The method of claim 1 , wherein the lysosomal storage disorder is selected from the group consisting of Niemann-Pick Type C disease, Niemann-Pick Type A disease, Wolman disease, Farber disease, and Tay Sachs diseas…
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.